ivacaftor/lumacaftor (Orkambi)

From Aaushi
Jump to navigation Jump to search

Indications

* most common mutation in cystic fibrosis

Dosage

Adverse effects

Mechanism of action

More general terms

Components

References

  1. FDA News Release. July 2, 2015 FDA approves new treatment for cystic fibrosis http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm